Combination of MCL-1 and BCL-2 inhibitors is a promising approach for a host-directed therapy for tuberculosis
Highlights Abstract Tuberculosis (TB) accounts for 1.6 million deaths annually and over 25% of deaths due to antimicrobial resistance. Mycobacterium tuberculosis (M.tb) drives MCL-1 expression (family member of